EA024893B9 - БЕНЗО[b][1,4]ОКСАЗИНОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ МОДУЛЯТОРОВ ЧУВСТВИТЕЛЬНЫХ К КАЛЬЦИЮ РЕЦЕПТОРОВ - Google Patents

БЕНЗО[b][1,4]ОКСАЗИНОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ МОДУЛЯТОРОВ ЧУВСТВИТЕЛЬНЫХ К КАЛЬЦИЮ РЕЦЕПТОРОВ

Info

Publication number
EA024893B9
EA024893B9 EA201370205A EA201370205A EA024893B9 EA 024893 B9 EA024893 B9 EA 024893B9 EA 201370205 A EA201370205 A EA 201370205A EA 201370205 A EA201370205 A EA 201370205A EA 024893 B9 EA024893 B9 EA 024893B9
Authority
EA
Eurasian Patent Office
Prior art keywords
benzo
calcium sensing
receptor modulators
sensing receptor
oxazin
Prior art date
Application number
EA201370205A
Other languages
English (en)
Russian (ru)
Other versions
EA201370205A1 (ru
EA024893B1 (ru
Inventor
Маноджкумар Рампрасад Шукла
Сарде Гангарам Анкуш
Пашпуте Дилип Випул
Маджид Башир Сайед
Махадео Бхаскар Трьямбаке
Четан Санджай Павар
Ганеш Навинчандра Готе
Санджеев Анант Кулкарни
Венката П. Палле
Раджендер Кумар Камбодж
Original Assignee
Люпин Атлантис Холдингс Са
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Люпин Атлантис Холдингс Са filed Critical Люпин Атлантис Холдингс Са
Publication of EA201370205A1 publication Critical patent/EA201370205A1/ru
Publication of EA024893B1 publication Critical patent/EA024893B1/ru
Publication of EA024893B9 publication Critical patent/EA024893B9/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D265/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/281,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/341,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/361,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/5381,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/18Drugs for disorders of the endocrine system of the parathyroid hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
EA201370205A 2011-03-18 2012-03-16 БЕНЗО[b][1,4]ОКСАЗИНОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ МОДУЛЯТОРОВ ЧУВСТВИТЕЛЬНЫХ К КАЛЬЦИЮ РЕЦЕПТОРОВ EA024893B9 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN367KO2011 2011-03-18
PCT/IB2012/051268 WO2012127388A1 (en) 2011-03-18 2012-03-16 Benzo [b] [1, 4] oxazin derivatives as calcium sensing receptor modulators

Publications (3)

Publication Number Publication Date
EA201370205A1 EA201370205A1 (ru) 2014-01-30
EA024893B1 EA024893B1 (ru) 2016-10-31
EA024893B9 true EA024893B9 (ru) 2017-01-30

Family

ID=54192843

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201370205A EA024893B9 (ru) 2011-03-18 2012-03-16 БЕНЗО[b][1,4]ОКСАЗИНОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ МОДУЛЯТОРОВ ЧУВСТВИТЕЛЬНЫХ К КАЛЬЦИЮ РЕЦЕПТОРОВ

Country Status (15)

Country Link
US (1) US9464063B2 (es)
EP (1) EP2686306B1 (es)
JP (1) JP6033835B2 (es)
KR (1) KR20140051846A (es)
CN (1) CN103459377B (es)
AP (1) AP2013007153A0 (es)
AU (1) AU2012232706B2 (es)
BR (1) BR112013023914A2 (es)
CA (1) CA2829466A1 (es)
EA (1) EA024893B9 (es)
IL (1) IL228461A0 (es)
MX (1) MX2013010670A (es)
SG (1) SG193331A1 (es)
WO (2) WO2012127385A1 (es)
ZA (1) ZA201306837B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9163001B2 (en) 2012-02-24 2015-10-20 Lupin Limited Substituted chroman compounds as calcium sensing receptor modulators
WO2013136288A1 (en) 2012-03-16 2013-09-19 Lupin Limited Substituted 3,4-dihydro-2h-benzo[b] [1,4]oxazine compounds as calcium sensing receptor modulators
IN2015MN00421A (es) 2012-08-27 2015-09-04 Lupin Ltd
TW201602062A (zh) 2013-08-12 2016-01-16 魯賓有限公司 取代聯苯基化合物作為鈣敏感受體調節劑
WO2015028938A1 (en) 2013-08-28 2015-03-05 Lupin Limited Substituted naphthalene compounds as calcium sensing receptor modulators
AU2014338549B2 (en) 2013-10-25 2017-05-25 Novartis Ag Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors
WO2015162538A1 (en) 2014-04-21 2015-10-29 Lupin Limited Heterocyclic compounds as calcium sensing receptor modulators for the treatment of hyperparathyroidism, chronic renal failure and chronic kidney disease
ES2756748T3 (es) 2014-10-03 2020-04-27 Novartis Ag Uso de derivados de piridilo bicíclicos de anillo fusionado como inhibidores de fgfr4
CN104464530B (zh) * 2014-11-18 2017-08-25 深圳市华星光电技术有限公司 曲面型显示装置
US9802917B2 (en) 2015-03-25 2017-10-31 Novartis Ag Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide
PT3319959T (pt) 2015-07-06 2021-12-06 Alkermes Inc Inibidores hetero-halo de histona desacetilase
US10421756B2 (en) 2015-07-06 2019-09-24 Rodin Therapeutics, Inc. Heterobicyclic N-aminophenyl-amides as inhibitors of histone deacetylase
WO2017037616A1 (en) 2015-08-31 2017-03-09 Lupin Limited Arylalkylamine compounds as calcium sensing receptor modulators
EP3551176A4 (en) * 2016-12-06 2020-06-24 Merck Sharp & Dohme Corp. ANTIDIABETIC HETEROCYCLIC COMPOUNDS
SI3570834T1 (sl) 2017-01-11 2022-05-31 Alkermes, Inc. Biciklični inhibitorji histonske deacetilaze
CN111032040B (zh) 2017-08-07 2023-08-29 罗丹疗法公司 组蛋白去乙酰酶的双环抑制剂
AU2020415502A1 (en) * 2019-12-27 2022-07-14 Lupin Limited Pharmaceutical composition of CaSR modulators and methods and uses thereof
CA3166512A1 (en) * 2020-01-17 2021-07-22 Lupin Limited Methods, processes and intermediates for preparing chroman compounds

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001090069A1 (fr) * 2000-05-24 2001-11-29 Centre National De La Recherche Scientifique (Cnrs) Composes possedant une activite calcimimetique
EP1882684A1 (en) * 2005-05-19 2008-01-30 Astellas Pharma Inc. Pyrrolidine derivative or salt thereof
US20100029687A1 (en) * 2006-11-16 2010-02-04 Astellas Pharma Inc. Piperidine derivative or salt thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1109880A (zh) 1994-02-03 1995-10-11 合成实验室公司 3-(2-氨基乙基)-4-[3-(三氟甲基)苯甲酰基]-3,4-二氢-2h-1,4-苯并噁嗪衍生物、制备及其应用
FR2812875B1 (fr) 2000-08-08 2003-12-12 Centre Nat Rech Scient Nouvelles diamines possedant une activite modulatrice des casr et leur mode de preparation
US6908935B2 (en) * 2002-05-23 2005-06-21 Amgen Inc. Calcium receptor modulating agents
US7105537B2 (en) 2003-01-28 2006-09-12 Bristol-Myers Squibb Company 2-substituted cyclic amines as calcium sensing receptor modulators
JPWO2004106280A1 (ja) 2003-05-28 2006-07-20 日本たばこ産業株式会社 CaSRアンタゴニスト
AU2006244074B2 (en) * 2005-05-09 2012-12-13 Hydra Biosciences, Inc. Compounds for modulating TRPV3 function
MX2009003673A (es) 2006-10-04 2009-04-22 Pfizer Prod Inc Derivados de piridido[4,3-d]pirimidin-4(3h)-ona como antagonistas de los receptores de calcio.
MX2009003981A (es) * 2006-10-26 2009-04-27 Amgen Inc Agentes moduladores del receptor de calcio.
CN101970394B (zh) 2007-11-23 2015-05-27 利奥制药有限公司 用于治疗疾病的新的环烃化合物
WO2010038895A1 (ja) 2008-10-03 2010-04-08 味の素株式会社 CaSRアゴニスト
WO2010042642A1 (en) 2008-10-08 2010-04-15 Amgen Inc. Calcium receptor modulating agents
WO2010090069A1 (ja) * 2009-02-05 2010-08-12 ヤンマー株式会社 Egr装置及びこれを備えたエンジン装置
WO2010136037A1 (en) 2009-05-27 2010-12-02 Leo Pharma A/S Novel calcium sensing receptor modulating compounds and pharmaceutical use thereof
WO2010150837A1 (ja) 2009-06-25 2010-12-29 第一三共株式会社 インドリン誘導体

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001090069A1 (fr) * 2000-05-24 2001-11-29 Centre National De La Recherche Scientifique (Cnrs) Composes possedant une activite calcimimetique
EP1882684A1 (en) * 2005-05-19 2008-01-30 Astellas Pharma Inc. Pyrrolidine derivative or salt thereof
US20100029687A1 (en) * 2006-11-16 2010-02-04 Astellas Pharma Inc. Piperidine derivative or salt thereof

Also Published As

Publication number Publication date
SG193331A1 (en) 2013-10-30
CN103459377A (zh) 2013-12-18
IL228461A0 (en) 2013-12-31
EA201370205A1 (ru) 2014-01-30
NZ616676A (en) 2015-09-25
ZA201306837B (en) 2015-05-27
AU2012232706B2 (en) 2016-12-15
MX2013010670A (es) 2013-12-06
CA2829466A1 (en) 2012-09-27
JP2014510097A (ja) 2014-04-24
BR112013023914A2 (pt) 2016-12-13
KR20140051846A (ko) 2014-05-02
WO2012127385A1 (en) 2012-09-27
US9464063B2 (en) 2016-10-11
WO2012127388A1 (en) 2012-09-27
CN103459377B (zh) 2016-09-07
EP2686306A1 (en) 2014-01-22
JP6033835B2 (ja) 2016-11-30
AP2013007153A0 (en) 2013-09-30
EP2686306B1 (en) 2017-01-04
US20140018358A1 (en) 2014-01-16
EA024893B1 (ru) 2016-10-31
AU2012232706A1 (en) 2013-09-26

Similar Documents

Publication Publication Date Title
EA024893B9 (ru) БЕНЗО[b][1,4]ОКСАЗИНОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ МОДУЛЯТОРОВ ЧУВСТВИТЕЛЬНЫХ К КАЛЬЦИЮ РЕЦЕПТОРОВ
UY33353A (es) Compuestos adecuados para el tratamiento de trastornos metabolicos y metodos de preparacion
MY162689A (en) Oxazoline and isoxazoline derivatives as crac modulators
WO2011116356A3 (en) Positive allosteric modulators of group ii mglurs
TN2015000429A1 (en) 3-acetylamino-1-(phenyl-heteroaryl-aminocarbonyl or phenyl-heteroaryl-carbonylamino)benzene derivatives for the treatment of hyperproliferative disorders
EA201692272A1 (ru) Модуляторы s1p
WO2012093809A3 (en) New bicyclic compound for modulating g protein-coupled receptors
EA201590951A1 (ru) Дигидропиразольные модуляторы gpr40
UY32888A (es) Dihidrobenzocicloalquiloximetil-oxazolopirimidinonas sustituidas, preparación y uso de las mismas
MX2015002755A (es) 1,3-dioxanomorfidas y 1,3-dioxanocodidas.
GEP20166474B (en) Pyrazolospiroketone derivatives for use as acetyl-coa carboxylase inhibitors
EA201590954A1 (ru) Дигидропиразольные модуляторы gpr40
MX2013012211A (es) Derivados biciclicos substituidos de metil amina como moduladores de receptores de esfingosina-1-fosfato.
EA201591805A1 (ru) Оксабицикло [2.2.2] кислоты - модуляторы gpr120
EA201590949A1 (ru) Дигидропиразольные модуляторы gpr40
MX2010002899A (es) Derivados de azaciclilisoquinolinona e isoindolinona como antagonistas de la histamina-3.
NZ700733A (en) (2-ureidoacetamido)alkyl derivatives as formyl peptide receptor 2 modulators
PH12014501891B1 (en) Substituted chroman compounds as calcium sensing receptor modulators
EA201591815A1 (ru) Бицикло [2.2.2] кислоты - модуляторы gpr120
CR20140495A (es) 5-amino[1,4]thiazines como inhibidores de bace1
PH12014501195A1 (en) Novel 2h-indazoles as ep2, receptor antagonists
IN2015MN00421A (es)
WO2013005168A3 (en) Cannabinoid receptor modulators
WO2012090179A3 (en) Isoquinoline derivatives as cannabinoid receptor modulators
MX2015005312A (es) Derivados de 1h-indazol-3-carboxamida y uso de los mismos como antagonistas de p2y12.

Legal Events

Date Code Title Description
TH4A Publication of the corrected specification to eurasian patent
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU